(18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy

(18)F‐FDG PET/CT scanning is routinely performed to stage and evaluate the treatment response in many malignancies. Immunotherapy is a rapidly growing treatment option for many cancers, and both clinicians and imaging specialists need to be familiar with (18)F‐FDG PET/CT imaging characteristics uniq...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherk, Martin H, Nadebaum, David P, Barber, Thomas W, Beech, Paul, Haydon, Andrew, Yap, Kenneth S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
MEDICAL IMAGING
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303622/
https://www.ncbi.nlm.nih.gov/pubmed/35191204
http://dx.doi.org/10.1111/1754-9485.13390
_version_ 1784751912323645440
author Cherk, Martin H
Nadebaum, David P
Barber, Thomas W
Beech, Paul
Haydon, Andrew
Yap, Kenneth S
author_facet Cherk, Martin H
Nadebaum, David P
Barber, Thomas W
Beech, Paul
Haydon, Andrew
Yap, Kenneth S
author_sort Cherk, Martin H
collection PubMed
description (18)F‐FDG PET/CT scanning is routinely performed to stage and evaluate the treatment response in many malignancies. Immunotherapy is a rapidly growing treatment option for many cancers, and both clinicians and imaging specialists need to be familiar with (18)F‐FDG PET/CT imaging characteristics unique to patients on this type of treatment. In particular, many immune‐related adverse events (irAEs) can be detected on (18)F‐FDG PET/CT and early accurate identification is critical to reduce treatment related morbidity and incorrect interpretation of malignant disease status. This pictorial essay reviews frequently encountered irAEs in clinical practice and their appearances on (18)F‐FDG PET/CT along with a brief discussion on pseudoprogression and hyperprogression.
format Online
Article
Text
id pubmed-9303622
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93036222022-07-28 (18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy Cherk, Martin H Nadebaum, David P Barber, Thomas W Beech, Paul Haydon, Andrew Yap, Kenneth S J Med Imaging Radiat Oncol MEDICAL IMAGING (18)F‐FDG PET/CT scanning is routinely performed to stage and evaluate the treatment response in many malignancies. Immunotherapy is a rapidly growing treatment option for many cancers, and both clinicians and imaging specialists need to be familiar with (18)F‐FDG PET/CT imaging characteristics unique to patients on this type of treatment. In particular, many immune‐related adverse events (irAEs) can be detected on (18)F‐FDG PET/CT and early accurate identification is critical to reduce treatment related morbidity and incorrect interpretation of malignant disease status. This pictorial essay reviews frequently encountered irAEs in clinical practice and their appearances on (18)F‐FDG PET/CT along with a brief discussion on pseudoprogression and hyperprogression. John Wiley and Sons Inc. 2022-02-22 2022-06 /pmc/articles/PMC9303622/ /pubmed/35191204 http://dx.doi.org/10.1111/1754-9485.13390 Text en © 2022 The Authors. Journal of Medical Imaging and Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Radiologists. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle MEDICAL IMAGING
Cherk, Martin H
Nadebaum, David P
Barber, Thomas W
Beech, Paul
Haydon, Andrew
Yap, Kenneth S
(18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy
title (18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy
title_full (18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy
title_fullStr (18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy
title_full_unstemmed (18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy
title_short (18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy
title_sort (18)f‐fdg pet/ct features of immune‐related adverse events and pitfalls following immunotherapy
topic MEDICAL IMAGING
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303622/
https://www.ncbi.nlm.nih.gov/pubmed/35191204
http://dx.doi.org/10.1111/1754-9485.13390
work_keys_str_mv AT cherkmartinh 18ffdgpetctfeaturesofimmunerelatedadverseeventsandpitfallsfollowingimmunotherapy
AT nadebaumdavidp 18ffdgpetctfeaturesofimmunerelatedadverseeventsandpitfallsfollowingimmunotherapy
AT barberthomasw 18ffdgpetctfeaturesofimmunerelatedadverseeventsandpitfallsfollowingimmunotherapy
AT beechpaul 18ffdgpetctfeaturesofimmunerelatedadverseeventsandpitfallsfollowingimmunotherapy
AT haydonandrew 18ffdgpetctfeaturesofimmunerelatedadverseeventsandpitfallsfollowingimmunotherapy
AT yapkenneths 18ffdgpetctfeaturesofimmunerelatedadverseeventsandpitfallsfollowingimmunotherapy

Ejemplares similares